» Articles » PMID: 36902175

When Just One Phosphate Is One Too Many: The Multifaceted Interplay Between Myc and Kinases

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Mar 11
PMID 36902175
Authors
Affiliations
Soon will be listed here.
Abstract

Myc transcription factors are key regulators of many cellular processes, with Myc target genes crucially implicated in the management of cell proliferation and stem pluripotency, energy metabolism, protein synthesis, angiogenesis, DNA damage response, and apoptosis. Given the wide involvement of Myc in cellular dynamics, it is not surprising that its overexpression is frequently associated with cancer. Noteworthy, in cancer cells where high Myc levels are maintained, the overexpression of Myc-associated kinases is often observed and required to foster tumour cells' proliferation. A mutual interplay exists between Myc and kinases: the latter, which are Myc transcriptional targets, phosphorylate Myc, allowing its transcriptional activity, highlighting a clear regulatory loop. At the protein level, Myc activity and turnover is also tightly regulated by kinases, with a finely tuned balance between translation and rapid protein degradation. In this perspective, we focus on the cross-regulation of Myc and its associated protein kinases underlying similar and redundant mechanisms of regulation at different levels, from transcriptional to post-translational events. Furthermore, a review of the indirect effects of known kinase inhibitors on Myc provides an opportunity to identify alternative and combined therapeutic approaches for cancer treatment.

Citing Articles

Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.

Hamilton G, Stickler S, Rath B Curr Cancer Drug Targets. 2024; 24(9):930-940.

PMID: 38275056 DOI: 10.2174/0115680096272757231211113206.


The Identification of Nuclear FMRP Isoform Iso6 Partners.

Ledoux N, Lelong E, Simard A, Hussein S, Adjibade P, Lambert J Cells. 2023; 12(24).

PMID: 38132127 PMC: 10742089. DOI: 10.3390/cells12242807.

References
1.
Chiappa M, Petrella S, Damia G, Broggini M, Guffanti F, Ricci F . Present and Future Perspective on PLK1 Inhibition in Cancer Treatment. Front Oncol. 2022; 12:903016. PMC: 9201472. DOI: 10.3389/fonc.2022.903016. View

2.
Dar A, Belkhiri A, El-Rifai W . The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene. 2008; 28(6):866-75. PMC: 2642527. DOI: 10.1038/onc.2008.434. View

3.
Chandriani S, Frengen E, Cowling V, Pendergrass S, Perou C, Whitfield M . A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One. 2009; 4(8):e6693. PMC: 2723908. DOI: 10.1371/journal.pone.0006693. View

4.
Hann S, Eisenman R . Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol. 1984; 4(11):2486-97. PMC: 369080. DOI: 10.1128/mcb.4.11.2486-2497.1984. View

5.
Song R, Hou G, Yang J, Yuan J, Wang C, Chai T . Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial-mesenchymal transition. Oncol Lett. 2018; 16(5):5739-5744. PMC: 6202541. DOI: 10.3892/ol.2018.9406. View